|
Authorized Generic Deals Are ‘Pay for Delay,’ FTC Tells Courts … Again
The FTC is challenging a GlaxoSmithKline (GSK)-Teva patent settlement deal, filing an amicus brief that argues authorized generic agreements fall under the category of pay-for-delay deals and are anticompetitive.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives